DelveInsight’s, “Treatment Resistant Depression Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Treatment Resistant Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Treatment Resistant Depression Research. Learn more about our innovative pipeline today! @ Treatment Resistant Depression Pipeline Outlook
Key Takeaways from the Treatment Resistant Depression Pipeline Report
- In November 2024:- COMPASS Pathways- A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression. This is a phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study. The study population will include participants aged ≥18 years with TRD.
- In October 2024: Mapreg- Double-blind,Controlled,Randomized Phase 2 Study of Efficacy,Safety,Pharmacokinetics& Pharmacodynamics of Daily Oral Administration of MAP4343 During 6 Weeks in Antidepressant Non-responders Patients Experiencing a Major Depressive Episode. This is a phase II, versus placebo, multicentre, double blind, randomized, parallel study in male or female patients with drug resistant depression.
- DelveInsight’s Treatment Resistant Depression pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Treatment Resistant Depression treatment.
- The leading Treatment Resistant Depression Companies such as Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, and others.
- Promising Treatment Resistant Depression Therapies such as GH001, VLS-01, Psilocybin, BPL-003, NV-5138, Ebselen, OSU6162, and others.
Stay informed about the cutting-edge advancements in Treatment Resistant Depression treatments. Download for updates and be a part of the revolution in care @ Treatment Resistant Depression Clinical Trials Assessment
Treatment Resistant Depression Emerging Drugs Profile
- Psilocybin: COMPASS Pathways
Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. The company has developed a synthesised formulation of psilocybin, COMP 360, and is investigating the effectiveness of psilocybin therapy, initially in treatment-resistant depression.
- AXS-05: Axsome Therapeutics
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor, an ionotropic glutamate receptor, and a sigma-1 receptor agonist. These actions modulate glutamatergic neurotransmission. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor
Learn more about Treatment Resistant Depression Drugs opportunities in our groundbreaking Myelofibrosis Research and development projects @ Treatment Resistant Depression Unmet Needs
Treatment Resistant Depression Companies
Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, and others.
Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Treatment Resistant Depression Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Discover the latest advancements in Treatment Resistant Depression treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Treatment Resistant Depression Market Drivers and Barriers, and Future Perspectives
Scope of the Treatment Resistant Depression Pipeline Report
- Coverage- Global
- Treatment Resistant Depression Companies- Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, and others.
- Treatment Resistant Depression Therapies- GH001, VLS-01, Psilocybin, BPL-003, NV-5138, Ebselen, OSU6162, and others.
- Treatment Resistant Depression Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Treatment Resistant Depression Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Treatment Resistant Depression Pipeline on our website @ Treatment Resistant Depression Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Treatment Resistant Depression: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Preregistration)
- AXS-05: Axsome Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Psilocybin: COMPASS Pathways
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- SEP-378614: Sumitomo Dainippon Pharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Treatment Resistant Depression Key Companies
- Treatment Resistant Depression Key Products
- Treatment Resistant Depression- Unmet Needs
- Treatment Resistant Depression- Market Drivers and Barriers
- Treatment Resistant Depression- Future Perspectives and Conclusion
- Treatment Resistant Depression Analyst Views
- Treatment Resistant Depression Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/